OPPORTUNISTIC INFECTION IMAGING IN AIDS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$46,211.00
Award Year:
1992
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
18937
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Rhomed Inc
1020 Tijeras Ne, Albuquerque, NM, 87106
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Teresa A Coons
(505) 344-7200
Business Contact:
() -
Research Institution:
n/a
Abstract
OPPORTUNISTIC INFECTIONS ARE A MAJOR CAUSE OF MORBIDITY AND MORTALITY IN AIDS PATIENTS. ALTHOUGH IT IS GENERALLY BELIEVED THAT THE EARLY DIAGNOSIS AND TREATMENT OF AN OPPORTUNISTIC INFECTION IS CRITICAL TO DECREASING MORBIDITY AND INCREASING OVERALL SURVIVAL, LOCALIZING THE SITE OF THESE INFECTIONS IS OFTEN DIFFICULT. CURRENTLY, THERE ARE TWO ACCEPTED TECHNIQUES FOR WHOLE-BODY EVALUATION USING RADIONUCLIDES: 111IN-OXINE-LABELED AUTOLOGOUS WHITE BLOOD CELL (WBC) SCINTIGRAPHY AND 67GA CITRATE SCINTIGRAPHY. THE OBJECTIVE OF THIS PROJECT IS TO TEST THE USE OF A 99MTC-LABELED, MONOCLONAL ANTIBODY-BASED IMAGING REAGENT FOR DETECTING HIDDEN INFECTIONS IN PATIENTS WITH AIDS. THE ANTIBODY BINDS TO THE SURFACES OF HUMAN NEUTROPHILS, THUS PERMITTING IN VIVO TAGGING OF THE CELLS MOST LIKELY TO BE FOUND AT THE SITE OF AN ABSCESS OR INFECTION. WE EXPECT THAT THE USE OF THE 99MTC-LABELED ANTIBODY WILL IMPROVE THE TIMELINESSAND ACCURACY OF DIAGNOSIS, AND WILL ELIMINATE THE RISKS ASSOCIATED WITH THE USE OF EX VIVO- LABELED, 111IN WHITE BLOOD CELLS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government